Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.76 |
| ▸ | PDE1A | P54750 | 1/20 | 0.76 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.76 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.76 |
| ▸ | PDE6C | P51160 | 1/20 | 0.56 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6198473 | 0.86 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL7354844 | 0.85 | PDE5A (0.70) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL6197841 | 0.82 | PDE5A (0.71) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL5827475 | 0.81 | PDE5A (0.75) | PDE5APDE6CPDE11A | |
| SCHEMBL6197049 | 0.81 | PDE5A (0.81) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL3841327 | 0.80 | PDE5A (0.59) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL3023423 | 0.80 | PDE5A (0.63) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL3835865 | 0.80 | PDE5A (0.58) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL6199648 | 0.80 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL7350274 | 0.80 | PDE5A (0.58) | PDE5APDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534511-B1 | The use of certain 6-arylpyrazolo(3,4-d)pyrimidin-4-ones, 2 arylquinazolin-4-ones, 2-arylpurin-6-ones and 2-arylpyrido(3,2- d)pyrimidin-4-ones, or a pharmaceutically acceptable salt thereof, forsexual disorders | PFIZER INC. | 2003-03-18 | — | — | US | claimed |
| EP-0793498-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 2002-12-11 | — | — | EP | claimed |
| US-20020128171-A1 | Methods for prevention and treatment of gastrointestinal disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-12 | — | — | US | claimed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | claimed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | claimed |
| EP-0995751-A2 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1993007149-A1 | PYRAZOLOPYRIMIDINONE ANTIANGINAL AGENTS | PFIZER LIMITED (GB) | 1993-04-15 | — | — | WO | claimed |
| EP-1331950-B1 | EX VIVO METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | UNIV JOHNS HOPKINS (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20070197560-A1 | cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction | NAEF RETO | 2007-08-23 | — | — | US | disclosed |
| US-6992070-B2 | Methods and compositions for nucleic acid delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050004222-A1 | Methods for prevention and treatment of gastrointestinal disorders | JOHNS HOPKINS UNIVERSITY | 2005-01-06 | — | — | US | disclosed |
| US-20040214831-A1 | cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction | NAEF RETO | 2004-10-28 | — | — | US | disclosed |
| US-6774128-B2 | ADMINISTERING TO THE MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND THAT INCREASES NITRIC OXIDE (NO) ACTIVITY AS MEASURED IN A STANDARD GASTRIC EMPTYING ASSAY | JOHNS HOPKINS UNIVERSITY | 2004-08-10 | — | — | US | disclosed |
| US-20010055570-A1 | Cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs); using specified pyrazolopyrimidinone or aminoquinazoline derivatives | NAEF RETO (CH) | 2001-12-27 | — | — | US | disclosed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | disclosed |
| US-6200980-B1 | ADMINISTERING PHENYL PURINONE COMPOUND FOR TREATING PRECANCEROUS LEISONS | CELL PATHWAYS, INC. | 2001-03-13 | — | — | US | disclosed |
| US-6100270-A | Bicyclic heterocyclic compounds for the treatment of impotence | PFIZER INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | disclosed |
| EP-0995751-A2 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1993007149-A1 | PYRAZOLOPYRIMIDINONE ANTIANGINAL AGENTS | PFIZER LIMITED (GB) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004222-A1 | Methods for prevention and treatment of gastrointestinal disorders | VIP, GIPR, IAPP | PDE5A 302/4885PDE1A 1228/4885PDE1B 1857/4885 |
| US-20020128171-A1 | Methods for prevention and treatment of gastrointestinal disorders | VIP, GIPR, IAPP | PDE5A 302/4885PDE1A 1228/4885PDE1B 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.